
|Articles|March 7, 2010
- August 2009
- Volume 3
- Issue 8
Update from BIG 1-98, Studies on PARP Inhibitors, Bevacizumab & GI Perforation, Oral Mucositis, Casopitant in CINV, and more
Author(s)Onclive Team
Key Takeaways
Advertisement
Articles in this issue
almost 16 years ago
Is PFS Enough for Approval?, PharmaFocus: Velcade, etc.almost 16 years ago
Treating Chemotherapy-Induced Emesisalmost 16 years ago
Highlights from European Hematology AssociationAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































